Evidence map›Paper›PMID 30244405›Full record

ArticleInflammation2019

Application of Deacetylated Poly-N-Acetyl Glucosamine Nanoparticles for the Delivery of miR-126 for the Treatment of Cecal Ligation and Puncture-Induced Sepsis.

Joy N Jones Buie, Yue Zhou, Andrew J Goodwin, James A Cook, John Vournakis, Marina Demcheva, Ann-Marie Broome, Suraj Dixit, Perry V Halushka, Hongkuan Fan

Open access · greenAbstract read
In one paragraph

Article in Inflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Role of miRNA dysregulation in sepsis.Molecular medicine (Cambridge, Mass.) · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Joy N Jones BuieDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, 173 Ashley Ave., MSC 908, CRI Room 610, Charleston, SC, 29425, USA.
Yue ZhouDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, 173 Ashley Ave., MSC 908, CRI Room 610, Charleston, SC, 29425, USA.
Andrew J GoodwinDepartment of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA.
James A CookDepartment of Neurosciences, Medical University of South Carolina, Charleston, SC, 29425, USA.
John VournakisMarine Polymer Technologies, Inc., Burlington, MA, 01803, USA.
Marina DemchevaMarine Polymer Technologies, Inc., Burlington, MA, 01803, USA.
Ann-Marie BroomeDepartment of Neurosciences, Medical University of South Carolina, Charleston, SC, 29425, USA.
Suraj DixitDepartment of Cell & Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, 29425, USA.
Perry V HalushkaDepartment of Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA.
Hongkuan FanDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, 173 Ashley Ave., MSC 908, CRI Room 610, Charleston, SC, 29425, USA. fanhong@musc.edu.ORCID http://orcid.org/0000-0002-9441-9405
Medical University of South Carolina · USMarine Polymer Technologies (United States) · USNanjing University of Chinese Medicine · CN

Funding

South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
TRAINING TO IMPROVE CARDIOVASCULAR THERAPIEST32HL007260 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MENICK, DONALD R. · 1985 to 2021
$11.1M
South Carolina Clinical & Translational Research Institute (SCTR)TL1TR001451 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FEGHALI-BOSTWICK, CAROL A. · 2015 to 2024
$4.6M
The Beneficial Effects of Endothelial Progenitor Cells in the Vascular Dysfunction of SepsisR01GM113995 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FAN, HONGKUAN · 2015 to 2019
$1.9M
The Role of Pericytes in the Vascular Dysfunction of SepsisR01GM130653 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FAN, HONGKUAN · 2018 to 2021
$1.3M
The Role of Circulating Micro RNAs in ARDS Pathogenesis and OutcomesK23HL135263 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GOODWIN, ANDREW J · 2017 to 2019
$537k
NCATS NIH HHS TL1 TR001451NCATS NIH HHS UL1 TR 001450NCATS NIH HHS UL1 TR001450NHLBI NIH HHS 1K23HL135263-01A1NHLBI NIH HHS K23 HL135263NHLBI NIH HHS T32 HL007260NIGMS NIH HHS R01 GM113995NIGMS NIH HHS R01GM113995NIGMS NIH HHS R01 GM130653
6 · The paper itself

Abstract

Sepsis is an acute inflammatory syndrome in response to infection. In some cases, excessive inflammation from sepsis results in endothelial dysfunction and subsequent increased vascular permeability leading to organ failure. We previously showed that treatment with endothelial progenitor cells, which highly express microRNA-126 (miR-126), improved survival in mice subjected to cecal ligation and puncture (CLP) sepsis. miRNAs are important regulators of gene expression and cell function, play a major role in endothelial homeostasis, and may represent an emerging therapeutic modality. However, delivery of miRNAs to cells in vitro and in vivo is challenging due to rapid degradation by ubiquitous RNases. Herein, we developed a nanoparticle delivery system separately combining deacetylated poly-N-acetyl glucosamine (DEAC-pGlcNAc) polymers with miRNA-126-3p and miRNA-126-5p and testing these combinations in vitro and in vivo. Our results demonstrate that DEAC-pGlcNAc polymers have an appropriate size and zeta potential for cellular uptake and when complexed, DEAC-pGlcNAc protects miRNA from RNase A degradation. Further, DEAC-pGlcNAc efficiently encapsulates miRNAs as evidenced by preventing their migration in an agarose gel. The DEAC-pGlcNAc-miRNA complexes were taken up by multiple cell types and the delivered miRNAs had biological effects on their targets in vitro including pERK and DLK-1. In addition, we found that delivery of DEAC-pGlcNAc alone or DEAC-pGlcNAc:miRNA-126-5p nanoparticles to septic animals significantly improved survival, preserved vascular integrity, and modulated cytokine production. These composite studies support the concept that DEAC-pGlcNAc nanoparticles are an effective platform for delivering miRNAs and that they may provide therapeutic benefit in sepsis.

Indexed as

AcetylglucosamineAnimalsCecumCytokinesDrug CarriersEndothelium, VascularLigationMiceMicroRNAsNanoparticlesPuncturesSepsisSurvival RateAcetylglucosamineCytokinesDrug CarriersMicroRNAsMIRN126 microRNA, mousepoly-N-acetyl glucosamineEndothelial dysfunctionInflammationmiRNA deliveryOrgan dysfunctionPolymicrobial sepsis

Identifiers

PMID30244405
PMCPMC6380957
OpenAlexW2893914219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.